Lung Cancer Surgery Market

Lung Cancer Surgery Market Overview

The global Lung Cancer Surgery Market size was valued at USD 4.73 billion in 2024 and is predicted to reach USD 6.33 billion by 2030 with a CAGR of 4.9% from 2025-2030.

The rise in the number of tobacco-addicted people in the world impacts the lungs of people and increases the chances of people being diagnosed with lung cancer that further accelerates the growth of the market. However, the high cost of cancer surgeries slows down the overall growth of the market. On the other hand, the introduction of targeted therapies such as alectinib and entrectinib is sure to create future opportunity for the growth of the market. 

In addition, leading companies in the market such as Accuray Incorporated and Siemens Healthineers AG among others are adopting various business strategies such as product launch and partnership to maintain their market position and expand their product lines. Targeted therapies allow doctors to treat the affected specifically with less invasive procedures.

Rising Tobacco Consumption Fuels the Growth of the Market

The increased incidence of lung cancer, connected with the growing consumption of addictive nicotine boosts necessities of surgeries for lung cancer. According to World Health Organization, 8 million people die annually due to tobacco use. More tobacco consumption leads to increased employing of advanced treatment methods to save the lives of lung cancer patients in turn boosting the market.

Increased Government Initiatives Boosts Market Growth

The growing government spending on research and development of new surgical methods in cancer patients drives the market growth. The financial spend allows the researchers to create new and better surgical methods, improving patient care and usage of innovative methods for treating lung cancer. 

Ministry of Health and Family Welfare reported that healthcare spending in India was around USD 10.69 billion in 2023. Additionally, Institute for Health Metrics and Evaluation reported that U.S. spent USD 4.30 trillion on biomedical research annually. The spend towards research alone was around 36 million. With such high spending towards research and development, the government aims to boost the innovation and availability of cutting-edge surgical methods, thus driving the lung cancer surgery market growth.

Rising Air Pollution fuels the Market Growth

Rising air pollution due to pollutants drives the lung cancer surgery market expansion. The pollutants trigger oxidative stress, inflammation, and DNA damage in lung cells, making people vulnerable to lungs cancer. According to the report published by the Union for International Cancer Control (UICC) in May 2024, air pollution alone accounts for about 29% of the lung cancer deaths. So, the rising air pollution drives the market growth of lung cancer treatment as inhalation of polluted air directly led to lung cancer.

High Cost for Surgical Procedures Hinders the Market Growth

The high cost associated with cancer surgical procedures, that require specialized equipment and skilled surgeons, is restraining the market by creating financial barriers for lower- and middle-income populations.

Introduction of Targeted Therapies Creates Future Opportunity

The launch of targeted therapies such as alectinib and entrectinib is likely to create future opportunities in the market for lung cancer surgery by potentially reducing the necessity for aggressive surgery. This advancement changes the scenario of treatment, leading to more targeted and less invasive treatments.

Market Segmentations and Scope of the Study 

The lung cancer surgery market report is segmented by type, procedure, approach, patient type, cancer stage, end-user and region. On the basis of type, the market is classified into surgical instruments, monitoring & visualizing system, endosurgical equipment, robotic-assisted thoracic surgery systems and others. On the basis of procedure, the market is segmented into lobectomy, segmentectomy, wedge resection and pneumonectomy. On the basis of approach, the market is divided into thoracotomy and minimally invasive surgery. On the basis of patient type, the market is bifurcated into male and female. On the basis of cancer stage, the market is characterized into stage i, stage ii, stage iii, and stage iv. On the basis of end-user, the market is classified into hospitals, ambulatory surgical centers, and others. Regional breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America region dominates the lung cancer surgery market share and is predicted to remain so during the forecast period. This is due to the rising population of individuals accustomed to the use of tobacco that is responsible for causing a variety of diseases such as lung cancer and tumour. Based on the recent report released by Global Action, about 62.9 million people were addicted to tobacco use in the U.S. This increase in addicted population for tobacco use elevates the prevalence of lung cancer, that in turn fuel the demand for the treatment of lung cancer.

In addition, the increasing air pollution in the region caused by automobile exhausts and industrial processes further enhance the risk of developing lung cancer. As per the American Lung Association (ALA), about 131.2 million people suffer from particle pollution and reside in places with poor air quality. This increased risk to health increases the demand for effective lung cancer treatments and preventive measures, thereby driving the lung cancer surgery market demand.
On the other hand, the Asia-Pacific region is steadily growing in lung cancer surgery due to increasing incidents of lung cancer in this region. According to the World Cancer Research Fund International (WCRF International) report, China had a major share of cancer cases, that is 1,060,584, followed by Japan, with around 136,723, while India falls third, with 81,748 cases. These growing cases of lung cancer increase the demand for effective surgical procedures, thereby driving the growth of the market.

Additionally, governmental initiatives supporting families financially for treatment of ailments further boost the market in this region. For instance, the Indian government launched Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) to cover protective medical treatments for families. These support initiatives improve access to health services, that in turn enlarges the commercial space for advanced medical treatments such as lung cancer surgery significantly.

Competitive Landscape

Various key players operating in the lung cancer surgery industry are Medtronic, Siemens Healthineers AG, Accuray Incorporated, Karl Storz Se & Co. KG, Olympus Corporation, Intuitive Surgical Operations, Inc., Ethicon, Inc., AngioDynamics, Teleflex Incorporated, Scanlan International SRN, Baton Rouge General, Ackermann Instrumente GmbH, Trokamed GmbH, Phoenix Surgical (PTY) Ltd., KLS Martin Group, and others. These market players are adopting various strategies such as product launches and collaborations to remain dominant in the market. 

In June 2024, for example, Accuray Incorporated launched the Accuray Precision treatment planning software, that is aiming at improving the accuracy and intensity of radiation therapy. This is meant to improve on-target accuracy while minimizing damage to surrounding healthy tissues.

In January 2024, Siemens Healthineers AG partnered with City Cancer Challenge to promote sustainable cancer care solutions. The partnership intends to provide fuel for developing local health systems and enhancing access to quality cancer care, particularly in low- and middle-income countries.

In addition, Baton Rouge General recently introduced the Ion robotic-assisted technology, devoted entirely to the early diagnosis of lung cancer, in October 2023. The new technology uses a thinner, flexible catheter to snake its way through the lungs and take tissue samples for biopsy in a procedure safer and more accurate than ever before.

Key Benefits

• The report provides quantitative analysis and estimations of the lung cancer surgery market from 2025 to 2030, which assists in identifying the prevailing industry opportunities.

• The study comprises a deep-dive analysis of the current and future lung cancer surgery market trends to depict prevalent investment pockets in the industry.

• Information related to key drivers, restraints, and opportunities and their impact on the lung cancer surgery industry is provided in the report. 

• Competitive analysis of the key players, along with their market share is provided in the report.

• SWOT analysis and Porters Five Forces model is elaborated on the study.

• Value chain analysis in the market study provides a clear picture of roles of stakeholders.

Lung Cancer Surgery Market Key Segments

By Type

• Surgical Instruments

• Monitoring & Visualizing System

• Endosurgical Equipment

• Robotic-Assisted Thoracic Surgery Systems

• Others

By Procedure 

• Lobectomy

• Segmentectomy

• Wedge Resection

• Pneumonectomy 

By Approach 

• Thoracotomy

• Minimally Invasive Surgery 

By Patient Type

• Male 

• Female

By Cancer Stage

• Stage I

• Stage II

• Stage III

• Stage IV

By End-User

• Hospitals

• Ambulatory Surgical Centers

• Others 

By Region

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The UK

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia-Pacific 

• RoW

  • Latin America

  • Middle East 

  • Africa

Key Players

• Medtronic

• Siemens Healthineers AG

• Accuray Incorporated

• Karl Storz Se & Co. Kg

• Intuitive Surgical Operations, Inc.

• Ethicon, Inc.

• AngioDynamics

• Teleflex Incorporated

• Scanlan International SRN

• Baton Rouge General

• Ackermann Instrumente GmbH

• Trokamed GmbH

• Phoenix Surgical (PTY) Ltd.

• KLS Martin Group 

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size in 2024	USD 4.73 billion
Revenue Forecast in 2030	USD 6.33 billion
Growth Rate	CAGR of 4.9% from 2025 to 2030
Analysis Period	2024–2030
Base Year Considered	2024
Forecast Period	2025–2030
Market Size Estimation	Billion (USD)
Growth Factors	The growing tobacco-addicted population across the globe boosts the lung cancer surgery industry. The increasing government fundings for research and development of advanced lung cancer treatment is fueling the market growth. The rising air pollution drives the growth of the market.
Countries Covered	28
Companies Profiled	15
Market Share	Available for 10 companies
Customization Scope	Free customization (equivalent to up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.